ArticleGeneral thoracic and cardiovascular surgery2018
Sustained release of basic fibroblast growth factor using gelatin hydrogel improved left ventricular function through the alteration of collagen subtype in a rat chronic myocardial infarction model.
Article in General thoracic and cardiovascular surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Hydrogels in Cardiac Surgery: Versatile Platforms for Tissue Repair, Adhesion Prevention, and Localized Therapeutics.Gels (Basel, Switzerland) · 2025Review
- Modified bFGF targeting connective tissue growth factor in the injured microenvironment improved cardiac repair after chronic myocardial ischemia.Regenerative therapy · 2025Article
- Backflow reduction in local injection therapy with gelatin formulations.Drug delivery · 2024Article
- Hydrogel-based cardiac repair and regeneration function in the treatment of myocardial infarction.Materials today. Bio · 2024Review
- Investigation of the effectiveness of gelatin hydrolysate in human iPS-RPE cell suspension transplantation.Regenerative therapy · 2024Article
- Chitosan-Polyethylene Glycol Inspired Polyelectrolyte Complex Hydrogel Templates Favoring NEO-Tissue Formation for Cardiac Tissue Engineering.Gels (Basel, Switzerland) · 2024Article
- Application of Hydrogels in Cardiac Regeneration.Cardiology and therapy · 2023Review
- A deep dive into the darning effects of biomaterials in infarct myocardium: current advances and future perspectives.Heart failure reviews · 2022Review
- Progress in Gelatin as Biomaterial for Tissue Engineering.Pharmaceutics · 2022Review
- Hydrogels and Hydrogel Nanocomposites: Enhancing Healthcare through Human and Environmental Treatment.Advanced healthcare materials · 2022Review
- Fabrication of gentamicin loaded Col-I/HA multilayers modified titanium coatings for prevention of implant infection.Frontiers in chemistry · 2022Article
- Therapeutic Acellular Scaffolds for Limiting Left Ventricular Remodelling-Current Status and Future Directions.International journal of molecular sciences · 2021Review
- Strategies Using Gelatin Microparticles for Regenerative Therapy and Drug Screening Applications.Molecules (Basel, Switzerland) · 2021Review
- Biomaterial-Assisted Regenerative Medicine.International journal of molecular sciences · 2021Review
- Secreted frizzled-related protein 2, a novel mechanism to induce myocardial ischemic protection through angiogenesis.Basic research in cardiology · 2020Article
- Basic fibroblast growth factor attenuates left-ventricular remodeling following surgical ventricular restoration in a rat ischemic cardiomyopathy model.General thoracic and cardiovascular surgery · 2020Article
- Toward Regeneration of the Heart: Bioengineering Strategies for Immunomodulation.Frontiers in cardiovascular medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveChronic myocardial infarction (CMI) tends to be resistant to treatments possibly due to extensive solid fibrotic scar, hypoxia mediated by poorly vascularized environment, and/or inflammation and apoptosis. Here we aimed to testify the therapeutic effects of sustained release of basic fibroblast growth factor (bFGF) using gelatin hydrogel (GH) in a rat chronic MI model and to elucidate the therapeutic mechanism including the alteration of extracellular matrix component.
methodsCMI model rats are prepared by the permanent ligation of proximal left anterior descending coronary artery. After 4 weeks, GH sheets (GHSs) with bFGF (100 µg) (bFGF group) or with phosphate-buffered saline (Vehicle group) were implanted to the CMI models to evaluate the effect of bFGF-GHS on chronic scar tissue. Sham operation group was also prepared (n = 5 for each).
results4 weeks after implantation, bFGF-GHS significantly improved cardiac contractile function (fractional shortening: 21.8 ± 1.1 vs 21.5 ± 1.3 vs 29.7 ± 1.8%; P < 0.001/fractional area change: 33.0 ± 1.4 vs 34.1 ± 2.3 vs 40.6 ± 1.8%; P < 0.001) (Sham vs Vehicle vs bFGF) accompanied with neovascularization. Immunohistochemical studies revealed that bFGF-GHS increased collagen III/I ratio indicating the alteration of solid scar tissue. Quantitative RT-PCR results showed a decrease of collagen I mRNA expression within border MI zone.
conclusionsThe implantation of bFGF-GHS altered the collagen subtype of the fibrotic scar more suitable for tissue repair. The treatment of sustained-release bFGF may be promising for ischemic heart disease through chronic pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.